| Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial.J Headache Pain | PMID 39748312PMC11696797 | 2025-Jan-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial.JAMA Netw Open | PMID 39874036PMC11775734 | 2025-Jan-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39074566无 PMCID | 2025-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.Haematologica疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。 | PMID 39113672PMC11694132 | 2025-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.J Neurosurg | PMID 39126720无 PMCID | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials.J Natl Cancer Inst | PMID 39128018PMC11717417 | 2025-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).Int J Cancer | PMID 39198970无 PMCID | 2025-Jan-01 | 0.85 | Report is a secondary analysis of a phase III trial focused on long-term toxicities and quality-of-life in survivorship, not an original report of time-to-event efficacy. No drug-containing intervention is described in this specific analysis; the intervention refers to the survivorship program structure. No OS/PFS/DFS/EFS/RFS/TTP/Kaplan-Meier/HR data are reported. | 待处理 |
| Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinoma.J Natl Cancer Inst疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39222012无 PMCID | 2025-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.J Rheumatol | PMID 39406403无 PMCID | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.Vaccine | PMID 39536455无 PMCID | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.Vaccine | PMID 39536477无 PMCID | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.JAMA Oncol | PMID 39541202PMC11565370 | 2025-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.JAMA Cardiol | PMID 39550721PMC11571069 | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.JAMA Neurol | PMID 39556389PMC11574721 | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.JAMA Oncol | PMID 39570583PMC11583021 | 2025-Jan-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.JAMA Dermatol | PMID 39602111PMC11736510 | 2025-Jan-01 | 0.85 | The study is a randomized Phase III trial with a drug intervention and reports long-term safety and efficacy. However, it is excluded because it is not an oncology study (focus is on plaque psoriasis, not a malignant neoplasm) and lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The reported efficacy outcomes are categorical response rates (PASI 75/90, sPGA 0/1), which do not qualify as time-to-event endpoints for Kaplan-Meier digitization. | 待处理 |
| Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial.Hum Reprod | PMID 39673334PMC11700900 | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response.Clin Transl Gastroenterol | PMID 39853721PMC11756870 | 2025-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial.Expert Opin Drug Saf | PMID 38682328无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide.J Hepatol | PMID 39009085无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The treatment effect across ASPECTS in acute ischemic stroke: Analysis from the AcT trial.Int J Stroke | PMID 39086232PMC11669262 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.AIDS Behav | PMID 39225890PMC11739274 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.Ann Hematol | PMID 39227450PMC11868237 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.Lancet Infect Dis | PMID 39243794无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39243945无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).Adv Ther | PMID 39249591PMC11782436 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Subcutaneous versus intravenous nivolumab for renal cell carcinoma.Ann Oncol | PMID 39288844无 PMCID | 2025-Jan | 0.90 | The study is an oncology, human, randomized, Phase III trial with a drug-containing intervention (nivolumab) and reports original results. However, the primary endpoint is pharmacokinetic non-inferiority, and the key secondary endpoint is objective response rate (ORR), which is not a time-to-event efficacy endpoint. No time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP) or associated Kaplan-Meier/HR analyses are reported or indicated. | 待处理 |
| Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution.Ophthalmology | PMID 39293681无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.Ann Oncol | PMID 39299443无 PMCID | 2025-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.Ann Oncol | PMID 39313156无 PMCID | 2025-Jan | 0.90 | The record describes a biomarker/genomic analysis of circulating tumor DNA from a Phase III randomized trial (MONALEESA), but it does not report on survival, progression, recurrence, death, or any other efficacy outcome (primary, secondary, or time-to-event). It is a correlative science report, not an efficacy report. | 待处理 |
| Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.J Am Acad Dermatol | PMID 39332633无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab.Ann Allergy Asthma Immunol | PMID 39343385无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.Adv Ther | PMID 39347926无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study.J Am Acad Dermatol | PMID 39349183无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39369790无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109.Ann Surg Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39373925无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.AIDS Behav | PMID 39375290PMC11739242 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.Diabetes Obes Metab | PMID 39375869PMC11618241 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.Breast Cancer | PMID 39379782PMC11717841 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.Nat Med | PMID 39385046PMC11750718 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials.JACC Heart Fail | PMID 39387766无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIG 1.:森林图/亚组分析图;FIG 2.:森林图/亚组分析图。 | PMID 39393026PMC11687940 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39393777无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Artificial intelligence-based analysis of retinal fluid volume dynamics in neovascular age-related macular degeneration and association with vision and atrophy.Eye (Lond) | PMID 39406933PMC11732971 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association between trajectory of systolic blood pressure and outcomes in heart failure patients with preserved ejection fraction (HFpEF).Eur J Intern Med | PMID 39419733无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes Metab | PMID 39434431PMC11618291 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113.Int J Clin Oncol | PMID 39441453无 PMCID | 2025-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial.Am J Clin Dermatol | PMID 39441519PMC11742000 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.Br J Haematol | PMID 39442921PMC11739754 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).Respir Med | PMID 39481660无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |